Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
pCAR-19B in CD19-positive Relapsed/Refractory B-ALL
NCT05334823Phase 2Recruiting
- Sponsor
- Chongqing Precision Biotech
- Start
- Jan 2022
- Primary completion
- Dec 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of priscabtagene autoleucel in acute lymphoblastic leukemia (ALL), sponsored by Chongqing Precision Biotech. Started Jan 2022; status: recruiting.
02
Drugs
priscabtagene autoleucel
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT05334823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05334823.